Zymeworks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Zymeworks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Zymeworks Today - Breaking & Trending Today

Zymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call Transcript

Zymeworks Inc. (NYSE:ZYME) Q1 2024 Earnings Call Transcript May 2, 2024 Zymeworks Inc. misses on earnings expectations. Reported EPS is $-0.41513 EPS, expectations were $-0.31. Zymeworks Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you for standing by. […] ....

United States , Ken Galbraith , Tritce Co , Humanized Xenograft Model , Paul Moore , Clinical Development ,

Zymeworks (NYSE:ZYME) Reaches New 1-Year High at $12.71

Shares of Zymeworks Inc. (NYSE:ZYME – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $12.71 and last traded at $12.52, with a volume of 90247 shares trading hands. The stock had previously closed at $12.37. Zymeworks Stock Performance The firm has a market […] ....

Kenneth Galbraith , Paul Andrew Moore , Zymeworks Company Profile , Blackrock Inc , Zymeworks Inc , Acadian Asset Management , Securities Exchange Commission , Get Free Report , Exchange Commission , Capital Management , Street Corp , Asset Management , Zymeworks Daily , Nyse Zyme ,

Zymeworks (NYSE:ZYME) Reaches New 12-Month High at $12.71

Zymeworks Inc. (NYSE:ZYME – Get Free Report) shares hit a new 52-week high on Tuesday . The stock traded as high as $12.71 and last traded at $12.52, with a volume of 90247 shares changing hands. The stock had previously closed at $12.37. Zymeworks Stock Performance The firm has a fifty day simple moving average […] ....

United States , Christopher Astle , Paul Andrew Moore , Securities Exchange Commission , Zymeworks Company Profile , Ameritas Investment Partners Inc , Virtus Fund Advisers , Life Insurance Co , Zymeworks Inc , Get Free Report , Exchange Commission , Capital Management , Fund Advisers , Employees Retirement System , Ameritas Investment Partners , Zymeworks Daily , Nyse Zyme ,

Zymeworks Inc CEO Kenneth Galbraith Sells 23,904 Shares

Zymeworks Inc (NASDAQ:ZYME), a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of next-generation multifunctional biotherapeutics, recently witnessed a significant insider sell. ....

Zymeworks Inc , Iopharmaceutical Company , Kenneth Galbraith , Nsider Transactions ,

Zymeworks Inc. (NYSE:ZYME) CFO Christopher Astle Sells 4,563 Shares

Zymeworks Inc. (NYSE:ZYME – Get Free Report) CFO Christopher Astle sold 4,563 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The shares were sold at an average price of $10.65, for a total transaction of $48,595.95. Following the completion of the sale, the chief financial officer now owns 7,934 […] ....

United States , Christopher Astle , Zymeworks Inc , Life Insurance Co , Ameritas Investment Partners Inc , Get Free Report , Trading Down , Capital Management , Employees Retirement System , Investment Partners , Quantbot Technologies , Zymeworks Daily , Nyse Zyme , Insider Trading , Nsider Trades ,